Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Journal of Global Health|December 24, 2013
Availability, prices and affordability of essential medicines in HaitiHarinder Singh Chahal, Nazaire St Fort, Lisa BeroJAMA Internal Medicine|February 15, 2021
Contents of US Food and Drug Administration Refuse-to-File Letters for New Drug Applications and Efficacy Supplements and Their Public Disclosure by ApplicantsHarinder Singh Chahal, Sanjana Mukherjee, Daniel W Sigelman, et al.Revista Panamericana De Salud Publica = Pan American Journal of Public Health|October 6, 2016
Establishing a regulatory value chain model: An innovative approach to strengthening medicines regulatory systems in resource-constrained settingsHarinder Singh Chahal, Farrah Kashfipour, Matt Susko, et al.JAMA Network Open|November 1, 2022
Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021Andrea N Monge, Daniel W Sigelman, Robert J Temple, et al.BMJ Global Health|June 5, 2018
Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatmentHarinder Singh Chahal, Peter Capella, Ryan Presto, et al.Journal of the International AIDS Society|December 13, 2017
The US Food and Drug Administration's tentative approval process and the global fight against HIVHarinder Singh Chahal, Jeffrey S Murray, Martin Shimer, et al.JAMA Network Open|November 21, 2019
An Evaluation of US Food and Drug Administration's Program to Register HIV Drugs for Use in Resource-Constrained SettingsHarinder Singh Chahal, Kalli Koukounas, Peter Capella, et al.Pageof 1